公开(公告)号：US20240345092A1

公开(公告)日：2024-10-17

申请号：US18682668

申请日：2022-08-10

Applicant: RANDOX LABORATORIES LTD.

Inventor： Stephen Peter Fitzgerald ,  Mark Ruddock ,  John Lamont ,  Declan McKenna

IPC: G01N33/574

CPC classification number: G01N33/57434 ,  G01N33/57488

Abstract: Single markers lack both sensitivity and specificity to stratify risk of PCa in patients who present with elevated tPSA and abnormal DRE. The novel combination of serum markers identified in this study could be employed to help triage patients into ‘low’ and ‘high’ risk categories, allowing general practitioners (GPs) to improve management of patients in primary care settings and potentially reducing the number of referrals for unnecessary, invasive, and costly treatments.